Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate (Business Wire)

Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate

UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with a contract to manufacture a novel live attenuated tularemia vaccine. The contract value is $6.3 million.

“Ology Bio is pleased to be working with the DOD and our colleagues at Appili Therapeutics to advance this important new vaccine candidate,” said Dr. Peter Khoury, president and CEO at Ology Bio. “Tularemia remains an important biological threat but to date no licensed vaccine exists to protect against this disease.”

Learn more about Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate.
X